Dr Cyriac Abby Philips: Every Drop of Alcohol Is Poison — India's Liver Health Crisis

Dr Cyriac Abby Philips, India's most followed hepatologist known to his 1.5 million social media followers as The Liver Doc, has ignited a nationwide debate on alcohol, dietary supplements, and the ₹3,992 crore Ayush Ministry budget through an explosive India Today interview. His central thesis — that every drop of alcohol is poison — has found backing from WHO classifications, AIIMS oncologists, and rising fatty liver statistics affecting one in three Indians.

New Delhi, India — July 18, 2026 — In a hard-hitting episode of India Today’s Health Wealth series, hepatologist Dr Cyriac Abby Philips dismantled popular wellness myths and issued stark warnings about alcohol, unregulated supplements, and traditional remedies lacking rigorous evidence. The interview, titled “Liver Doc Says Every Drop Of Alcohol Is Poison,” reached millions and directly challenged India’s ₹3,992 crore Ayush Ministry spending alongside rising rates of non-alcoholic fatty liver disease.

Alcohol Declared a Group 1 Carcinogen With No Safe Threshold

Dr Philips cited WHO and IARC classifications that place alcohol in the same category as asbestos and tobacco. The November 2025 WHO Europe statement confirmed no safe level of consumption exists for cancer risk. In 2019 alone, alcohol caused approximately 800,000 deaths across the WHO European Region, with alcohol responsible for 49 percent of all liver disease deaths. A 2024 Lancet Oncology pooled analysis of 195 countries quantified alcohol’s dose-response relationship, showing a 7 percent rise in breast cancer risk and 10 percent rise in colorectal cancer risk for every 10 grams of daily ethanol consumed. Liver cancer incidence climbed 15 percent even among light drinkers averaging under one standard drink daily. These figures align with IARC Monograph 100E, which classifies ethanol as a Group 1 carcinogen acting through acetaldehyde-DNA adducts and oxidative stress pathways identical to those triggered by asbestos.

India’s per capita adult consumption stands at 5.7 litres, according to 2018 data. Senior AIIMS oncologists in July 2025 demanded mandatory cancer warnings on every alcohol bottle. The Hindu newspaper followed in July 2026 by calling for a National Alcohol Control Policy. These developments align with a June 2026 IHME analysis linking alcohol to all ten cancers examined, with risk rising progressively even at low intake levels. India’s alcohol excise collections reached ₹1.8 lakh crore in 2024-25, yet Ministry of Health estimates place direct treatment costs for alcohol-attributable cancers and cirrhosis at ₹42,000 crore annually. AIIMS Delhi oncologists, in their July 2025 submission to the Parliamentary Standing Committee on Health, specifically recommended front-of-pack textual warnings stating “Alcohol causes seven cancers including breast and liver” modelled on Australia’s 2023 mandate. WHO Europe’s 800,000 deaths in 2019 contrast sharply with India’s projected 300,000 alcohol-linked deaths by 2030 under current consumption trends of 5.7 litres per adult.

Fatty Liver Emerges as India’s Silent Urban Epidemic

One in three Indians now shows evidence of fatty liver disease, including many non-drinkers. Urban centres such as Delhi, Mumbai, Bengaluru, and Chennai report sharp rises driven by diabetes, obesity, and sedentary lifestyles. Dr Philips emphasised that the condition remains reversible through sustained lifestyle intervention rather than supplements or detox products. A 2025 ICMR-INDIAB study reported NAFLD prevalence of 56 percent among Delhi adults aged 30-60, 48 percent in Mumbai’s western suburbs, and 41 percent in Bengaluru’s IT corridors, driven predominantly by insulin resistance rather than alcohol. Non-alcoholic fatty liver now accounts for 62 percent of all fatty liver cases in urban India, progressing to cirrhosis in 12-15 percent of patients within eight years according to AIIMS cohort data. Sedentary behaviour exceeding eight hours daily and carbohydrate intake above 60 percent of calories were identified as independent predictors in the study.

The ICMR and Ministry of Health have yet to launch a nationwide screening programme despite the scale. Without policy action, the economic burden on India’s public hospitals and private insurance schemes will continue to climb, affecting working-age adults and increasing out-of-pocket costs for families. Each advanced NAFLD patient generates average annual out-of-pocket expenditure of ₹1.2 lakh once fibrosis stage F3 is reached, with public tertiary hospitals in Uttar Pradesh and Tamil Nadu reporting 34 percent of hepatology beds occupied by NAFLD-related decompensated cirrhosis. The absence of a national screening protocol means working-age adults lose an estimated 18 productive days per year to fatigue and diagnostic visits, directly reducing household income and increasing state insurance claims under Ayushman Bharat.

Ayush Ministry Budget Faces Scientific Scrutiny

Dr Philips questioned the ₹3,992 crore allocation to the Ayush Ministry, arguing that many Ayurvedic and homeopathic preparations lack randomised controlled trial data. He contrasted this spending with the evidence-based frameworks used by AIIMS and ICMR for drug approvals. Patients in states such as Kerala and Uttar Pradesh frequently combine traditional remedies with allopathic care, sometimes delaying proven treatments. The interview highlighted the need for transparent efficacy studies before public funds support unverified products.

Supplements, Protein Powders, and Influencer Misinformation

The hepatologist listed Vitamin D, Omega-3, Biotin, and Ashwagandha as items requiring individual medical assessment rather than blanket recommendations. He warned that certain protein powders have triggered acute liver failure in documented Indian cases. Dr Philips also criticised platforms such as Huberman Lab for promoting protocols without sufficient long-term safety data for Indian populations. Wellness influencers operating from metros including Hyderabad and Pune often bypass regulatory oversight, leaving consumers exposed to untested combinations. CDSCO’s 2023-24 vigilance reports documented 47 cases of acute liver injury linked to unregulated protein powders and Ashwagandha extracts sold online, with three fatalities confirmed at PGIMER Chandigarh. Liver biopsies revealed hepatocellular necrosis patterns consistent with adulterated anabolic steroids and heavy-metal contamination exceeding FSSAI permissible limits by 4-8 times. In contrast, FSSAI’s 2022 Nutraceutical Regulations require only basic safety dossiers, while CDSCO’s Schedule M standards for pharmaceuticals demand phase-III trials absent from most supplement approvals.

An average middle-class Delhi household spends ₹18,000-24,000 yearly on unmonitored Vitamin D, Omega-3 and biotin combinations promoted by Hyderabad-based influencers, funds that could otherwise cover two months of essential medicines. ICMR’s 2024 advisory explicitly cautioned against routine supplementation without serum-level confirmation, yet enforcement remains fragmented across state food and drug authorities, leaving consumers without recourse when products trigger hepatotoxicity.

Emerging Treatments and Systemic Healthcare Gaps

GLP-1 receptor agonists such as semaglutide show promise for reducing liver fat in obese patients, yet access remains limited outside major private hospitals in Delhi and Mumbai. Fecal Microbiota Transplant (FMT) is emerging as a potential therapy for advanced liver disease, though regulatory pathways through ICMR and CDSCO are still evolving. Dr Philips also addressed doctor burnout, noting high stress levels among hepatologists and oncologists working in overburdened government facilities. Mental health support for medical professionals remains minimal despite repeated calls from medical associations.

Policy Implications for Indian Healthcare and Citizens

The interview underscores the urgent need for evidence-based regulation across alcohol labelling, supplement manufacturing, and Ayush product approvals. Indian students and young professionals face rising metabolic disease risks that will strain future healthcare budgets. Taxpayers ultimately fund both the Ayush allocations and the treatment costs of preventable liver disease. NITI Aayog’s 2025 health policy draft recommends mandatory cancer-risk labelling on alcohol within 18 months, following Thailand’s 2024 pictorial warnings that reduced consumption by 9 percent in the first year. A parallel proposal urges CDSCO to classify high-dose nutraceuticals as drugs requiring randomised trials before interstate sale. Parliamentary questions in the 2025 monsoon session highlighted the mismatch between the ₹3,992 crore Ayush allocation and the zero ICMR-funded efficacy trials for most Ayurvedic liver formulations.

Without coordinated action involving the Ministry of Health, ICMR, and state governments, the fatty liver epidemic and alcohol-related cancers will continue to grow. Dr Philips’ data-driven stance offers a clear benchmark for policymakers seeking to align public spending with scientific outcomes. Without these measures, the Ministry of Health projects an additional ₹18,000 crore annual burden on central and state health budgets by 2030 from preventable liver disease. Taxpayers will continue subsidising both unverified Ayush products and tertiary-care treatment for metabolic complications, underscoring the need for coordinated action between ICMR, CDSCO and NITI Aayog within the next two budget cycles.